Assessment of Hepatitis C management on glycemic control among Type 2 Diabetes Mellitus patients

Document Type : Original Article

Authors

1 Community Medicine, National Research Center, Cairo, Egypt

2 Faculty of Graduate studies and Environmental Research, Ain Shams University, Cairo, Egypt

3 Endocrinology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

4 Community Medicine Department, National Research Center, Cairo, Egypt

5 Community Medicine department, National Research Center, Cairo, Egypt

Abstract

Background: HCV and DM are chronic diseases of high global prevalence. Many studies proved the association between Hepatitis C and DM in the last three decades and this consists of an interrelated association; moreover, HCV infection triggers Diabetes Mellitus, most probably type 2.
Objective: To assess the possibility of the improvement of T2DM in patients with HCV when applying the new DAA HCV treatment in Egypt.
Patients and Methods: The current study is a prospective cohort hospital-based study that aims to describe the association between T2DM on one hand and chronic HCV on the other hand after successful management of HCV through the DAAs according to the protocol of the Ministry of Health. SVR was defined as undetectable HCV RNA levels at 12 weeks after the end of treatment (EOT). Fasting plasma glucose (FPG) levels between 100–125 mg/dL were defined as prediabetes and FPG ≥ 126 mg/dL was defined as diabetes. We have found positive correlation between management of HCV using DAAs in general and improvement of HbA1c and FPG. Moreover, we reported stronger correlation between achieving SVR and the HbA1c level and FPG.
Results: After 12 weeks of follow-up, 82% of the patients maintained negative SVR, hemoglobin reduction was -0.6±0.4 %, 3 months after HCV treatment with a P value

Keywords

Main Subjects

Files

History

  • Receive Date: 15 November 2021
  • Revise Date: 10 December 2021
  • Accept Date: 12 December 2021

Share

How to cite

Statistics